Graves Light Lenhart Wealth Inc. Sells 200 Shares of Bristol-Myers Squibb (NYSE:BMY)

Graves Light Lenhart Wealth Inc. cut its holdings in Bristol-Myers Squibb (NYSE:BMY) by 3.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,516 shares of the biopharmaceutical company’s stock after selling 200 shares during the period. Graves Light Lenhart Wealth Inc.’s holdings in Bristol-Myers Squibb were worth $312,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of BMY. Rosenberg Matthew Hamilton grew its stake in Bristol-Myers Squibb by 68.6% in the 4th quarter. Rosenberg Matthew Hamilton now owns 1,705 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 694 shares during the period. Greenfield Savings Bank boosted its holdings in shares of Bristol-Myers Squibb by 3.3% in the 4th quarter. Greenfield Savings Bank now owns 27,766 shares of the biopharmaceutical company’s stock worth $1,570,000 after buying an additional 889 shares during the last quarter. Grandview Asset Management LLC bought a new position in Bristol-Myers Squibb during the fourth quarter valued at about $275,000. Marcum Wealth LLC increased its holdings in Bristol-Myers Squibb by 11.5% during the fourth quarter. Marcum Wealth LLC now owns 19,103 shares of the biopharmaceutical company’s stock worth $1,080,000 after buying an additional 1,964 shares during the last quarter. Finally, FNY Investment Advisers LLC raised its position in Bristol-Myers Squibb by 17,657.1% in the fourth quarter. FNY Investment Advisers LLC now owns 12,430 shares of the biopharmaceutical company’s stock worth $703,000 after acquiring an additional 12,360 shares during the period. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Stock Performance

Shares of BMY opened at $55.35 on Tuesday. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $61.08. The company has a current ratio of 1.24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83. The company has a market cap of $112.26 billion, a PE ratio of -15.42, a price-to-earnings-growth ratio of 15.20 and a beta of 0.45. The stock has a 50-day moving average price of $57.44 and a 200-day moving average price of $51.66.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.31. The business had revenue of $11.89 billion during the quarter, compared to analyst estimates of $11.26 billion. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. Bristol-Myers Squibb’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same period in the previous year, the business posted $2.00 earnings per share. As a group, equities analysts forecast that Bristol-Myers Squibb will post 0.93 earnings per share for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd will be given a dividend of $0.62 per share. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. The ex-dividend date is Friday, January 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 4.48%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -69.08%.

Insiders Place Their Bets

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 1,830 shares of the business’s stock in a transaction on Friday, November 1st. The stock was acquired at an average cost of $54.67 per share, for a total transaction of $100,046.10. Following the completion of the transaction, the executive vice president now directly owns 62,109 shares in the company, valued at approximately $3,395,499.03. This represents a 3.04 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Phil M. Holzer sold 700 shares of the firm’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $55.62, for a total value of $38,934.00. Following the transaction, the senior vice president now directly owns 11,760 shares in the company, valued at $654,091.20. This trade represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.09% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on BMY shares. Barclays raised their price target on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the stock an “underweight” rating in a research note on Monday, October 7th. Daiwa Capital Markets upgraded Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a research note on Wednesday, November 13th. BMO Capital Markets increased their price target on Bristol-Myers Squibb from $57.00 to $61.00 and gave the stock a “market perform” rating in a research note on Tuesday, November 12th. UBS Group lifted their target price on shares of Bristol-Myers Squibb from $50.00 to $54.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 9th. Finally, Citigroup lifted their price objective on shares of Bristol-Myers Squibb from $55.00 to $60.00 and gave the company a “neutral” rating in a research note on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $56.27.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.